223 related articles for article (PubMed ID: 16980008)
21. Cancer in renal transplant recipients.
Sakellariou G; Memmos D; Alexopoulos E; Tsobanelis T; Sinakos Z; Papadimitriou M
Cancer Detect Prev; 1986; 9(3-4):389-93. PubMed ID: 3527417
[TBL] [Abstract][Full Text] [Related]
22. Posttransplant erythrocytosis in renal transplant recipients at Jeddah Kidney Center, Kingdom of Saudi Arabia.
Basri N; Gendo MZ; Haider R; Abdullah KA; Hassan A; Shaheen FA
Exp Clin Transplant; 2007 Jun; 5(1):607-9. PubMed ID: 17617052
[TBL] [Abstract][Full Text] [Related]
23. Use of sirolimus to facilitate steroid withdrawal from a cyclosporine regimen.
Kahan BD; Podbielski J; Schoenberg L
Transplant Proc; 2006 Nov; 38(9):2842-6. PubMed ID: 17112844
[TBL] [Abstract][Full Text] [Related]
24. Cancers after renal transplantation: multicenter experience.
Harzallah K; Abderrahim E; Chareffedine K; Yeich S; Belhadj R; Skhiri H; Younsi F; Abdallah TB; Abdelletif A; Hachicha J; Hmida J; El May M; Khedr A; Manaa J
Saudi J Kidney Dis Transpl; 2008 Sep; 19(5):825-30. PubMed ID: 18711309
[TBL] [Abstract][Full Text] [Related]
25. No increase of melanoma after kidney transplantation in the northern part of The Netherlands.
Bastiaannet E; Homan-van der Heide JJ; Ploeg RJ; Hoekstra HJ
Melanoma Res; 2007 Dec; 17(6):349-53. PubMed ID: 17992116
[TBL] [Abstract][Full Text] [Related]
26. Mucosa-associated lymphoid tissue gastric lymphoma regression in a renal transplant patient after conversion of the immunosuppression to sirolimus: a case report.
Lasmar EP; Coelho LG; Lasmar MF; Lasmar LF; Lima PV; Nogueira AF
Transplant Proc; 2009 Apr; 41(3):959-61. PubMed ID: 19376398
[TBL] [Abstract][Full Text] [Related]
27. Immunosuppression modifications and graft outcome in patients with chronic allograft nephropathy.
El-Agroudy AE; El-Dahshan K; Mahmoud K; Ismail AM; El-Baz M; Shokeir AA; Ghoneim MA
Exp Clin Transplant; 2008 Sep; 6(3):203-10. PubMed ID: 18954298
[TBL] [Abstract][Full Text] [Related]
28. Transitional cell carcinoma in renal transplant recipients: a single center experience.
Li XB; Xing NZ; Wang Y; Hu XP; Yin H; Zhang XD
Int J Urol; 2008 Jan; 15(1):53-7. PubMed ID: 18184173
[TBL] [Abstract][Full Text] [Related]
29. Melanomas in renal transplant recipients.
Le Mire L; Hollowood K; Gray D; Bordea C; Wojnarowska F
Br J Dermatol; 2006 Mar; 154(3):472-7. PubMed ID: 16445778
[TBL] [Abstract][Full Text] [Related]
30. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.
Carmellini M; Collini A; Ruggieri G; Garosi G; Bernini M
Transplant Proc; 2008; 40(6):1858-61. PubMed ID: 18675070
[TBL] [Abstract][Full Text] [Related]
31. Cold ischemia is a major determinant of acute rejection and renal graft survival in the modern era of immunosuppression.
Mikhalski D; Wissing KM; Ghisdal L; Broeders N; Touly M; Hoang AD; Loi P; Mboti F; Donckier V; Vereerstraeten P; Abramowicz D
Transplantation; 2008 Apr; 85(7 Suppl):S3-9. PubMed ID: 18401260
[TBL] [Abstract][Full Text] [Related]
32. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia.
Fernández A; Marcén R; Pascual J; Galeano C; Ocaña J; Arellano EM; Alfaro C; Villafruela JJ; Burgos FJ; Ortuño J
Transplant Proc; 2006 Oct; 38(8):2453-5. PubMed ID: 17097965
[TBL] [Abstract][Full Text] [Related]
33. Rapid steroid discontinuation for pediatric renal transplantation: a single center experience.
Lau KK; Haddad MN; Berg GM; Perez RV; Butani L
Pediatr Transplant; 2007 Aug; 11(5):504-10. PubMed ID: 17631018
[TBL] [Abstract][Full Text] [Related]
34. Immunosuppression and other risk factors for lip cancer after kidney transplantation.
van Leeuwen MT; Grulich AE; McDonald SP; McCredie MR; Amin J; Stewart JH; Webster AC; Chapman JR; Vajdic CM
Cancer Epidemiol Biomarkers Prev; 2009 Feb; 18(2):561-9. PubMed ID: 19190169
[TBL] [Abstract][Full Text] [Related]
35. Kaposi sarcoma in solid organ transplant recipients: a single center report.
Boeckle E; Boesmueller C; Wiesmayr S; Mark W; Rieger M; Tabarelli D; Graziadei I; Hoefer D; Antretter H; Stelzmueller I; Krugmann J; Zangerle R; Huemer H; Poelzl G; Margreiter R; Bonatti H
Transplant Proc; 2005 May; 37(4):1905-9. PubMed ID: 15919500
[TBL] [Abstract][Full Text] [Related]
36. Malignancies after kidney transplantation.
Rascente M; Pisani F; Barletta A; D'Angelo M; Giammaria A; Parzanese I; Rizza V; Iaria G; Famulari A
Transplant Proc; 2005; 37(6):2529-31. PubMed ID: 16182735
[TBL] [Abstract][Full Text] [Related]
37. Ciclosporin A tapering monitored by NFAT-regulated gene expression: a new concept of individual immunosuppression.
Sommerer C; Giese T; Schmidt J; Meuer S; Zeier M
Transplantation; 2008 Jan; 85(1):15-21. PubMed ID: 18192906
[TBL] [Abstract][Full Text] [Related]
38. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
39. The impact of renal failure on survival following cardiac transplantation.
Sezgin A; Akay TH; Gültekin B; Ozkan S; Ozdemir N; Aşlamaci S
Transplant Proc; 2007 May; 39(4):1247-9. PubMed ID: 17524945
[TBL] [Abstract][Full Text] [Related]
40. [Characteristics of neoplasm occurrence of renal allograft recipients and their prognosis].
Wang CX; Liu LS; Chen LZ; Wu PG; Xie D; Fei JG; Qiu J; Deng SX; Zheng KL; Ji YL; Zhu LY; Shen QR; He XS
Ai Zheng; 2005 Feb; 24(2):222-5. PubMed ID: 15694039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
